MP43: Prostate Cancer: Localized: Active Surveillance

Room 222
Moderated Poster
Oncology: Prostate

Information

Format
In PersonOn Demand

MP43: Prostate Cancer: Localized: Active Surveillance

MP43-01: Clinical Significance of Detection of Perineural Invasion in Low-risk men on Active Surveillance

Sunday, May 15, 2022 10:30 AM to 11:45 AM
Room 222
Claire De La Calle · Johns Hopkins Univeristy

MP43-02: Preference elicitation and treatment decision making among men diagnosed with localized prostate cancer: Results from the Healium Trial.

Sunday, May 15, 2022 10:30 AM to 11:45 AM
Room 222
Michael Diefenbach

MP43-03: Active surveillance for low-risk prostate cancer: time trends and variation in the AUA Quality (AQUA) Registry

Sunday, May 15, 2022 10:30 AM to 11:45 AM
Room 222
Matthew Cooperberg · UCSF Comprehensiv Cancer Center

MP43-04: Comparison of 4K score, Prostate Health Index, and PSA density in Active Surveillance

Sunday, May 15, 2022 10:30 AM to 11:45 AM
Room 222
Bruce Trock

MP43-05: Upfront MRI is the new standard, have confirmatory biopsies become obsolete?

Sunday, May 15, 2022 10:30 AM to 11:45 AM
Room 222
Ivo De Vos · Erasmus MC

MP43-06: Comparing MRI/US Fusion to Standard Prostate Biopsy in Determining Grade Reclassification at Confirmatory Biopsy in a Multi-Institutional Active Surveillance Cohort: A Pennsylvania Urology Regional Collaborative (PURC) Analysis

Sunday, May 15, 2022 10:30 AM to 11:45 AM
Room 222
David Strauss · Temple University Hospital / Fox Chase Cancer Center

MP43-07: Negative Prostate MRI as a Predictor of Disease Stability in Patients on Active Surveillance

Sunday, May 15, 2022 10:30 AM to 11:45 AM
Room 222
Jacob Enders · Urologic Oncology Branch, NCI

MP43-08: Active Surveillance for prostate cancer: uptake over time and the impact of an organized protocol

Sunday, May 15, 2022 10:30 AM to 11:45 AM
Room 222
Sebastiaan Remmers · Erasmus MC

MP43-09: Risk of Adverse Pathology after Deferred Prostatectomy for Grade Group 1 and 2 Prostate Cancer Being Managed by Active Surveillance

Sunday, May 15, 2022 10:30 AM to 11:45 AM
Room 222
Cheyenne Williams · University of Pennsylvania / National Cancer Institute

MP43-10: Impact of family history and germline genetic risk variants on long-term outcomes of active surveillance-eligible prostate cancer

Sunday, May 15, 2022 10:30 AM to 11:45 AM
Room 222
Keyan Salari · Massachusetts General Hospital

MP43-11: The Use and Outcomes of Men with NCCN Favorable Intermediate Risk Prostate Cancer Managed with Active Surveillance

Sunday, May 15, 2022 10:30 AM to 11:45 AM
Room 222
Roshan Paudel · University of Michigan

MP43-12: Impact of NCCN-Compliant Multidisciplinary Conference on the Utilization of Active Surveillance for Patients with Localized Prostate Cancer

Sunday, May 15, 2022 10:30 AM to 11:45 AM
Room 222
Yousuf Ramahi · Roswell Park Comprehensive Cancer Center

MP43-13: Interlaboratory Gleason Grading Variation Affects Treatment: a Dutch Historic Cohort Study in 30,509 Prostate Cancer Patients

Sunday, May 15, 2022 10:30 AM to 11:45 AM
Room 222
Rachel Flach

MP43-14: External validation of a model predicting increase in Gleason grade for men on Active Surveillance in the GAP3 consortium database

Sunday, May 15, 2022 10:30 AM to 11:45 AM
Room 222
Daan Nieboer · Erasmus MC

MP43-15: A 5-year Prospective Study of African American Men on Prostate Cancer Active Surveillance: Does Race Predict Upgrading?

Sunday, May 15, 2022 10:30 AM to 11:45 AM
Room 222
Joshua Pincus · Tulane University School of Medicine

MP43-16: Racial Disparities in Rates of Gleason Grade Reclassification in a Multi-Institutional Prostate Cancer Active Surveillance Cohort: A Pennsylvania Urology Regional Collaborative (PURC) Analysis

Sunday, May 15, 2022 10:30 AM to 11:45 AM
Room 222
Rohit Reddy · Temple University Hospital

MP43-17: Predicting True Pathologic Gleason Grade During Active Surveillance for Prostate Cancer: Calibration of the Johns Hopkins ActiveCare Model in Five Large Active Surveillance Cohorts

Sunday, May 15, 2022 10:30 AM to 11:45 AM
Room 222
Christian Pavlovich · Johns Hopkins Hospital

MP43-18: Prostate Cancer Mortality Rates in Low and Favorable Intermediate Risk Active Surveillance Patients: A Population-Based Competing Risks Analysis

Sunday, May 15, 2022 10:30 AM to 11:45 AM
Room 222
Rashid Sayyid · Augusta University

MP43-19: Drop-out Rates from Active Surveillance for Disease Progression Remain Consistent and Not Negligible Over Time. A Plea for Long-term Assessment Based on a Large, Prospectively Collected Active Surveillance Cohort

Sunday, May 15, 2022 10:30 AM to 11:45 AM
Room 222
Luigi Nocera · Ospedale San Raffaele

MP43-20: Long Term Health-Related Quality Of Life (HRQoL) Outcomes After Surgery, Radiotherapy, or Active Surveillance For Localized Prostate Cancer

Sunday, May 15, 2022 10:30 AM to 11:45 AM
Room 222
Eyal Kord · Virginia Mason Medical Center